Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two prostate pills instead of one: can doubling up on alpha blockers clear urine retention?

NCT ID NCT07815379

Symptom relief Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers compare two drug strategies for men with urinary symptoms caused by an enlarged prostate, also called benign prostatic obstruction. One group receives tamsulosin alone, a standard alpha blocker. The other receives tamsulosin plus silodosin, a second alpha blocker. The trial measures changes in symptom scores at one and three months, including in men who needed a catheter because they could not urinate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tamsulosin alone or tamsulosin plus silodosin, two alpha blocker drugs
What this could lead to
If the combination works better, doctors could offer a stronger pill-based option to men whose urinary symptoms and urine retention have not improved on a single alpha blocker.
What could go wrong
This is a modest Phase 4 study of 140 men, so results may not apply to everyone with BPH. Taking two alpha blockers may also increase side effects such as dizziness or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥40 years. Catheterized patients due to acute urine retention secondary to BPO. Patients with moderate and severe LUTS secondary to BPH as proven by IPSS (International Prostate Symptoms score) ≥8 and Qmax \<15 ml/sec with total void urine volume \>125 cc. Exclusion Criteria: Patients with neurological problems as: uncontrolled DM, parkinsonism and cerebral stroke. Patients with history of previous prostate surgery. Patients with complicated BPH necessitating intervention as: recurrent/persistent UTI, recurrent hematuria, bladder stones and indwelling urethral catheter due to chromic urine retention (CUR). Patients with suspected malignancy by abnormal Digital Rectal Examination (DRE) and or high PSA.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BPH (benign prostatic hyperplasia) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BPH (benign prostatic hyperplasia)

Contacts and locations

Locations

  • Urology and Nephrology Center, Mnasoura University

    Al Mansurah, Dakahlia Governorate, 35561, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.